AstraZeneca and Vanderbilt University have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia.
Several Vanderbilt researchers have collaborated with this year’s Nobel Chemistry winners.
When discovering drugs for brain disorders, it’s important to test the candidates in multiple ways to avoid advancing those with restricted physiological effects.
Drug-like molecules described by Vanderbilt researchers could lead to Parkinson’s treatments with fewer side effects.
Accessibility Tools